Comparison of Palonosetron Versus Granisetron to Prevent Postoperative Nausea and Vomiting in Idiopathic Scoliosis Spine Surgery Patients

What this Trial Is About

Researchers are comparing two antiemetic drugs, palonosetron and granisetron, to prevent early and delayed postoperative nausea and vomiting (PONV) in adolescents and adults with idiopathic scoliosis undergoing posterior spinal fusion surgery. The study focuses on patients receiving total intravenous anesthesia (TIVA) and evaluates the effectiveness of these drugs when combined with dexamethasone, a commonly used medication to reduce nausea and pain. The trial also aims to assess rescue antiemetic use, drug-related side effects, and patient satisfaction. Participants will be randomly assigned to receive either palonosetron at 1.5 mcg/kg before anesthesia or granisetron 1 mg intravenously at the start of wound closure. Both groups will receive dexamethasone as a baseline antiemetic. The surgery involves TIVA with remifentanil and propofol, and morphine will be administered before the end of surgery for pain management. The study is double-blinded and conducted at University Malaya Medical Centre with an estimated sample size of 92 patients. Participants will be monitored closely for nausea and vomiting at 1, 4, 12, 24, and 48 hours after surgery. Researchers will evaluate the incidence and severity of PONV, the need for additional antiemetics, adverse effects, and patient satisfaction. Standard anesthetic techniques and pain assessments will be followed throughout. The total participation period includes surgery and postoperative monitoring up to 48 hours.

A Comparison Between Palonosetron Versus Granisetron as PONV Prophylaxis in Scoliotic Patients Undergoing Spine Surgery